Heart Disease AI Software Maker Scores $27M
Summary
Euclid, a medical technology company out of Boston, MA, said it will commercialize its AI-based heart disease diagnosis software to market after garnering $27 million in a series B round. Euclid’s technology has FDA clearance and a CE mark in discerning plaque changes in cardiac tissue when compared to specimen histopathology. “We are so proud of the remarkable work our team has accomplished and this series B allows us to expand our commercial reach.” AI The company’s noninvasive software was developed to create quantifiable information on the tissue being evaluated in the heart using algorithms and machine learning. The company is also investigating the software’s utility with identifying the dilation capacity of a vessel and changes in fractional flow reserve (FFRct). “Elucids basis in histopathology is highly differentiated from competitive methods and is paramount to understanding the key drivers of atherosclerosis which cause ischemia and heart attacks,” said John Fichthorn of MedTex Ventures.